Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 29, 2025 07:00 ET | Source: EsoBiotec

EsoBiotec to Present Preclinical Proof-of-Concept Data for Its Off-the-Shelf ENaBL In Vivo Cell Therapy Platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy

Poster talk will present safety and efficacy data for ENaBL-T, a lentiviral vector for in vivo engineering of BCMA CAR T cells, which supported the first in vivo BCMA CAR-T cell therapy clinical trial...
March 17, 2025 03:00 ET | Source: EsoBiotec

EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition

MONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec SA, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, today...
January 08, 2025 07:00 ET | Source: EsoBiotec

EsoBiotec Doses First Patient in Investigator Initiated Trial of In Vivo BCMA CAR-T Candidate ESO-T01 for Multiple Myeloma

Initial clinical observations suggest high level of T cells reprogramming and CAR-T expansion at the starting dose without lymphodepletion At 28 days after a single dose of ESO-T01, no cancer cells...
December 11, 2024 07:00 ET | Source: EsoBiotec

EsoBiotec Begins Clinical Trial of In Vivo BCMA CAR-T Candidate ESO-T01 for Multiple Myeloma

ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stage Early clinical data are expected in second half of 2025 MONT-SAINT-GUIBERT, Belgium, Dec. 11, 2024 (GLOBE NEWSWIRE) --...